drugset / Trial / NCT01213992
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer® in patients suffering from Non-dialysis Dependent Chronic Kidney Disease.
Timeline
- Start
- 2012-03
- Primary completion
- 2012-10
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Iron isomaltoside 1000 | Unknown | 500 mg | Intravenous |
| Comparator | Iron isomaltoside 1000 | Unknown | 1000 mg | Intravenous |